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A B S T R A C T
Background
Opioid drugs, includingbuprenorphine, are commonly used to treat neuropathic pain, and are considered effective by someprofessionals.
Most reviews have examined all opioids together. This review sought evidence specifically for buprenorphine, at any dose, and by any
route of administration. Other opioids are considered in separate reviews.
Objectives
To assess the analgesic efficacy of buprenorphine for chronic neuropathic pain in adults, and the adverse events associated with its use
in clinical trials.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from inception to 11 June
2015, together with reference lists of retrieved papers and reviews, and two online study registries.
Selection criteria
We included randomised, double-blind studies of two weeks’ duration or longer, comparing any oral dose or formulation of buprenor-
phine with placebo or another active treatment in chronic neuropathic pain.
Data collection and analysis
Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality.
We did not carry out any pooled analyses.
Main results
Searches identified 10 published studies, and one study with results in ClinicalTrials.gov. None of these 11 studies satisfied our inclusion
criteria, and so we included no studies in the review.
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Authors’ conclusions
There was insufficient evidence to support or refute the suggestion that buprenorphine has any efficacy in any neuropathic pain
condition.
P L A I N L A N G U A G E S U M M A R Y
Buprenorphine for neuropathic pain in adults
Neuropathic pain is pain coming from damaged nerves. It is different from pain messages that are carried along healthy nerves from
damaged tissue (for example, a fall or cut, or arthritic knee). Neuropathic pain is often treated by different medicines (drugs) to those
used for pain from damaged tissue, which we often think of as painkillers. Medicines that are sometimes used to treat depression or
epilepsy can be very effective in some people with neuropathic pain. But sometimes opioid painkillers are used to treat neuropathic
pain.
Opioid painkillers are drugs like morphine. Morphine is derived from plants, but many opioids are also made by chemical synthesis
rather than being extracted from plants. Buprenorphine is one of these synthetic opioids. It is available in numerous countries for use as
a painkiller, and can be given by injection, as a tablet placed under the tongue, or as a patch that delivers the drug to the body through
the skin.
In June 2015, we performed searches to look for clinical trials where buprenorphine was used to treat neuropathic pain in adults. We
found no study that did this, and that met our requirements for the review.
There is no evidence to support or refute the suggestion that buprenorphine works in any neuropathic pain condition. Large, properly
conducted new clinical trials would be needed to provide evidence that buprenorphine worked in neuropathic pain conditions.
B A C K G R O U N D
This review is based on a template for reviews of drugs used to
relieve neuropathic pain. The aim is for all reviews to use the
same methods, based on new criteria for what constitutes reliable
evidence in chronic pain (Moore 2010a; Appendix 1).
Description of the condition
The 2011 International Association of the Study of Pain defini-
tion of neuropathic pain is “pain caused by a lesion or disease of
the somatosensory system” (Jensen 2011), based on an earlier con-
sensus meeting (Treede 2008). Neuropathic pain is a consequence
of a pathological maladaptive response of the nervous system to
’damage’ from a wide variety of potential causes. It is characterised
by pain in the absence of a noxious stimulus and may be sponta-
neous (continuous or paroxysmal) in its temporal characteristics
or be evoked by sensory stimuli (dynamic mechanical allodynia
where pain is evoked by light touch of the skin). Neuropathic
pain is associated with a variety of sensory loss (numbness) and
sensory gain (allodynia) clinical phenomena, the exact pattern of
which vary between patient and disease, perhaps reflecting differ-
ent pain mechanisms operating in an individual patient and there-
fore potentially predictive of response to treatment (Demant 2014;
Helfert 2015; von Hehn 2012). Pre-clinical research hypothesises
a bewildering array of possible pain mechanisms that may operate
in people with neuropathic pain, which largely reflect pathophys-
iological responses in both the central and peripheral nervous sys-
tems, including neuronal interactions with immune cells (Baron
2012; Calvo 2012; von Hehn 2012). Overall, the treatment gains
in neuropathic pain, to even the most effective of available drugs,
are modest (Finnerup 2015; Moore 2013a), and a robust classifi-
cation of neuropathic pain is not yet available (Finnerup 2013).
Neuropathic pain is usually divided according to the cause of
nerve injury. Theremay bemany causes, but some common causes
of neuropathic pain include diabetes (painful diabetic neuropa-
thy (PDN)), shingles (postherpetic neuralgia (PHN)), amputation
(phantom limb pain), neuropathic pain after surgery or trauma,
stroke or spinal cord injury, trigeminal neuralgia, and human im-
munodeficiency virus (HIV) infection.
Many people with neuropathic pain conditions are significantly
disabledwithmoderate or severe pain formany years. Chronic pain
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conditions comprised five of the 11 top-ranking conditions for
years lived with disability in 2010 (Vos 2012), and are responsible
for considerable loss of quality of life, employment, and increased
healthcare costs (Moore 2014a).
In systematic reviews, the overall prevalence of neuropathic pain
in the general population is reported to be between 7% and 10%
(van Hecke 2014), and about 7% in a systematic review of stud-
ies published since 2000 (Moore 2014a). In individual countries,
prevalence rates have been reported as 3.3% in Austria (Gustorff
2008), 6.9% in France (Bouhassira 2008), and up to 8% in theUK
(Torrance 2006). Some forms of neuropathic pain, such as PDN
and post-surgical chronic pain (which is often neuropathic in ori-
gin), are increasing (Hall 2008). The prevalence of PHN is likely
to fall if vaccination against the herpes virus becomes widespread.
Estimates of incidence vary between individual studies for par-
ticular origins of neuropathic pain, often because of small num-
bers of cases. In primary care in the UK between 2002 and 2005,
the incidences (per 100,000 person-years’ observation) were 28
(95% confidence interval (CI) 27 to 30) for PHN, 27 (26 to 29)
for trigeminal neuralgia, 0.8 (0.6 to 1.1) for phantom limb pain,
and 21 (20 to 22) for PDN (Hall 2008). However, the incidence
of trigeminal neuralgia has also been estimated at 4 in 100,000
per year (Katusic 1991; Rappaport 1994), and 12.6 per 100,000
person-years for trigeminal neuralgia and 3.9 per 100,000 per-
son-years for PHN in a study of facial pain in the Netherlands
(Koopman 2009). One systematic review of chronic pain demon-
strated that some neuropathic pain conditions, such as PDN, can
be more common than other neuropathic pain conditions, with
prevalence rates up to 400 per 100,000 person-years (McQuay
2007).
Neuropathic pain is known to be difficult to treat effectively, with
only a minority of individuals experiencing a clinically relevant
benefit from any one intervention. A multidisciplinary approach
is now advocated, with pharmacological interventions being com-
bined with physical or cognitive interventions, or both. Conven-
tional analgesics are usually not effective, but without evidence to
support or refute that view. Some people with neuropathic pain
may derive some benefit from a topical lidocaine patch or low
concentration topical capsaicin, though evidence about benefits is
uncertain (Derry 2012; Derry 2014). High concentration topical
capsaicinmay benefit some people with PHN (Derry 2013). Treat-
ment for neuropathic pain is more usually by so-called uncon-
ventional analgesics (pain modulators) such as antidepressants like
duloxetine and amitriptyline (Lunn 2014; Moore 2012b; Sultan
2008), or antiepileptics like gabapentin or pregabalin (Moore
2009; Moore 2014b; Wiffen 2013).
The proportion of people who achieve worthwhile pain relief (typ-
ically at least 50%pain intensity reduction;Moore 2013b) is small,
generally only 10% to 25% more than with placebo, with num-
bers needed to treat for an additional beneficial outcome (NNT)
usually between 4 and 10 (Kalso 2013; Moore 2013a). Neuro-
pathic pain is not particularly different from other chronic pain
conditions in that only a small proportion of trial participants have
a good response to treatment (Moore 2013a).
The current National Institute for Health and Care Excellence
(NICE) guidance suggests offering a choice of amitriptyline, du-
loxetine, gabapentin, or pregabalin as initial treatment for neu-
ropathic pain (with the exception of trigeminal neuralgia), with
switching if first, second, or third drugs tried are not effective or
not tolerated (NICE 2013). This concurs with other recent guid-
ance (Finnerup 2015).
Description of the intervention
Buprenorphine is a thebaine derivative opioid drug, classified as a
step III opioid analgesic by theWorldHealthOrganization (WHO
1996). It has mixed agonistic and antagonistic properties, with
opioid agonistic activity exerted on mu-opioid receptors and the
ORL-1 receptor; it is a kappa- and delta-opioid receptor antago-
nist (Kress 2009; Pergolizzi 2010; Walsh 2003). Buprenorphine
is metabolised predominantly by the liver and excreted in bile af-
ter de-alkylation and glucuronidation, though hepatic extraction
from blood may be more complicated (Bullingham 1984). The
pharmacokinetics of buprenorphine vary with route of administra-
tion. While the sublingual and intramuscular routes produce sim-
ilar outcomes in terms of pain relief, when taken orally, buprenor-
phine undergoes extensive pre-systemic elimination (Bullingham
1981; Bullingham 1983).
Buprenorphine is available in numerous countries for use as an
analgesic, and can be given by injection, as a sublingual tablet,
or as a transdermal patch (or plaster). Typical analgesic doses of
buprenorphine are 0.3 to 0.6 mg (intramuscular or intravenous)
and its analgesic effects last about six hours. Sublingual buprenor-
phine doses are typically 200 to 400 micrograms (µg) every six
to eight hours. It is prescribed in the management of cancer pain,
but not typically as a first-line opioid. It is also used in opioid-
dependence (Foster 2013).
Oral bioavailability of buprenorphine is low (15%) due to exten-
sive first-pass metabolism in the gastrointestinal mucosa and liver.
It is rapidly absorbed via the oral mucosa after sublingual adminis-
tration, but absorption into the systemic circulation is slow (max-
imum is 30 minutes to 3.5 hours after a single dose; one to two
hours with repeat dosing; Elkader 2005). However, it does have a
long duration of action (six to eight hours), which is thought to
be due to an unusually slow dissociation constant for the drug-
receptor complex. Naloxone is relatively ineffective in reversing
opioid effects from buprenorphine, despite naloxone having high
affinity for the mu-receptor (Gal 1989).
There was a ceiling effect for respiratory depression within the
doses studied, but not for analgesia (Dahan 2005; Dahan 2006).
While buprenorphine has been shown to slow intestinal tran-
sit, it possibly does this less than morphine (Bach 1991); impor-
tantly, constipation as an adverse effect may be less severe (Pace
2007). Buprenorphine also exerts little or no pressure on pancre-
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atic and biliary ducts, distinguishing it from morphine in this re-
spect (Staritz 1986).Comparedwith other opioids, buprenorphine
causes little or no immunosuppression (Budd 2004; Sacerdote
2000; Sacerdote 2008). Buprenorphine does not accumulate in
renal failure and it is not removed by haemodialysis, and analgesia
is unaffected (Filitz 2006; Hand 1990).
Because buprenorphine is highly lipid-soluble, it is ideal for
transdermal delivery. Buprenorphine patch preparations for twice
weekly or weekly use are available with a range of transdermal drug
delivery rates (5, 10, 20, 35, 52.5, 70 µg/hour). NICE suggests
that a transdermal buprenorphine patch of 20 µg/hour equates
to approximately 30 mg of oral morphine daily (NICE 2012).
Buprenorphine via either the transdermal or injectable route is
approved for managing moderate to severe chronic pain. Sublin-
gual tablets and a sublingual film preparations are also available
in some countries and are sometimes combined with naloxone.
While these are usually used for the treatment of opioid addiction,
some sublingual tablets (200 and 400 µg) without naloxone are
available for chronic moderate to severe pain.
Transdermal buprenorphine has been suggested to be of value in
treating chronic non-cancer pain (Kusnik 2008; Sittl 2005), in-
cluding neuropathic pain after traumatic amputation, central neu-
ropathic pain, and HIV neuropathy (Canneti 2013; Hakl 2012;
Licina 2013; Weiner 2012). However, these are case reports, case
series, or post-marketing analyses rather than randomised trials.
How the intervention might work
Opioids such as buprenorphine bind to specific opioid receptors
in the nervous system and other tissues; there are three principal
classes of receptors (mu, kappa, and delta) although others have
been suggested, and subtypes of receptors are considered to ex-
ist. Binding of opioid agonists such as buprenorphine to receptors
brings about complex cellular changes, outcomes of which include
decreased perception of pain, decreased reaction to pain, and in-
creased pain tolerance. Opioids from plant sources have been used
for thousands of years to treat pain.
Why it is important to do this review
One UK survey found that weak and strong opioids were used
frequently for treating neuropathic pain (Hall 2013). Many clin-
icians (primary care and pain specialists) consider that buprenor-
phine has an important place in the management of chronic pain
conditions (Pergolizzi 2010).When compared with other opioids,
buprenorphine has a better adverse effect and safety profile. De-
spite this, buprenorphine (patches in particular) is often ’black-
listed’ on formularies, meaning that prescribing the drug is not
approved or allowed. This is reported to be on the basis of lack of
good-quality evidence. Since the early-2000s, a marked increase
in prescribing of opioids for non-cancer pain in general despite
a relatively modest evidence base has, in some countries, led to
widespread diversion with consequent abuse, misuse, and mortal-
ity (Franklin 2014). Concurrently, suspicion has arisen that opi-
oid-induced hyperalgesia, together with tolerance to the analgesic
effects of opioids, may in reality result in a lesser degree of benefit
for opioids in neuropathic pain than previously assumed.
The standards used to assess evidence in chronic pain trials have
evolved substantially in recent years, with particular attention be-
ing paid to trial duration, withdrawals, and statistical imputation
following withdrawal, all of which can substantially alter estimates
of efficacy. The most important change is the move from using
mean pain scores, or mean change in pain scores, to the number
of people who have a large decrease in pain (by at least 50%) and
who continue in treatment, ideally in trials of eight to 12 weeks’
duration or longer. Pain intensity reduction of 50% or more cor-
relates with improvements in co-morbid symptoms, function, and
quality of life. These standards are set out in the PaPaS Author and
Referee Guidance for pain studies of the Cochrane Pain, Palliative
and Supportive Care Group (PaPaS 2012).
This Cochrane review assessed evidence using methods that make
both statistical and clinical sense, and used developing criteria
for what constitutes reliable evidence in chronic pain (Moore
2010a). For inclusion and analysis, trials had to meet a minimum
of reporting quality (blinding, randomisation), validity (duration,
dose and timing, diagnosis, outcomes, etc), and size (ideally at
least 500 participants in a comparison in which the NNT is 4 or
above; Moore 1998). This approach sets high standards for the
demonstration of efficacy andmarks a departure from how reviews
were conducted previously.
Taking this newer, more rigorous approach is particularly impor-
tant for opioids in chronic non-cancer pain. Opioids in clinical
trials in non-cancer pain are associated with very high withdrawal
rates of up to 60% over about 12 weeks (Moore 2010b). Many
withdrawals occur within the first few weeks, when people ex-
perience pain relief but cannot tolerate the drug. The common
practice of using the last observed results carried forward to the
end of the trial many weeks later (last observation carried forward
(LOCF)) can, therefore, produce results based largely on people
who are no longer in the trial, and who in the real world could
not achieve pain relief because they could not take the tablets. The
newer standards, outlined in Appendix 1, would not allow this and
can produce very different results. For example, one large analysis
of pooled data from trials in osteoarthritis and chronic low back
pain conducted over about 12 weeks judged oxycodone effective,
but an analysis of the same data using the new clinically mean-
ingful standards showed it to be significantly worse than placebo
(Lange 2010).
One previous Cochrane review demonstrated the limitations of
our knowledge about opioids in neuropathic pain, except in short
duration studies of 24 hours or less (McNicol 2013). These limi-
tations were confirmed by a review specific to oxycodone (Gaskell
2014). A review specific to buprenorphine is timely.
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O B J E C T I V E S
To assess the analgesic efficacy of buprenorphine for chronic neu-
ropathic pain in adults, and the adverse events associated with its
use in clinical trials.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) with double-
blind assessment of participant outcomes following two weeks of
treatment or longer, though the emphasis of the review was on
studies of eight weeks or longer. We required full journal publica-
tion, with the exception of online clinical trial results summaries
of otherwise unpublished clinical trials and abstracts with suffi-
cient data for analysis. We did not include short abstracts (usually
meeting reports). We excluded studies that were non-randomised,
studies of experimental pain, case reports, and clinical observa-
tions.
Types of participants
Studies included adults aged 18 years and above with one or more
chronic neuropathic pain condition including (but not limited
to):
1. cancer-related neuropathy;
2. central neuropathic pain;
3. complex regional pain syndrome (CRPS) Type II;
4. human immunodeficiency virus (HIV) neuropathy;
5. painful diabetic neuropathy (PDN);
6. phantom limb pain;
7. postherpetic neuralgia (PHN);
8. postoperative or traumatic neuropathic pain;
9. spinal cord injury;
10. trigeminal neuralgia.
Where studies included participants with more than one type of
neuropathic pain, we planned to analyse results according to the
primary condition.
Types of interventions
Buprenorphine at any dose, by any route, administered for the
relief of neuropathic pain and compared with placebo or any active
comparator.
Types of outcome measures
We anticipated that studies would use a variety of outcome mea-
sures, with the majority of studies using standard subjective scales
(numerical rating scale (NRS) or visual analogue scale (VAS)) for
pain intensity or pain relief, or both. We were particularly inter-
ested in Initiative on Methods, Measurement, and Pain Assess-
ment in Clinical Trials (IMMPACT) definitions for moderate and
substantial benefit in chronic pain studies (Dworkin 2008). These
are defined as:
1. at least 30% pain relief over baseline (moderate);
2. at least 50% pain relief over baseline (substantial);
3. much or very much improved on Patient Global Impression
of Change scale (PGIC; moderate);
4. very much improved on PGIC (substantial).
These outcomes are different from those used in many earlier
reviews, concentrating as they doondichotomous outcomeswhere
pain responses do not follow a normal (Gaussian) distribution.
People with chronic pain desire high levels of pain relief, ideally
more than 50% pain intensity reduction, and ideally having no
worse than mild pain (Moore 2013b; O’Brien 2010).
We planned to include a ’Summary of findings’ table as set out
in the author guide (PaPaS 2012). We have not included a ’Sum-
mary of findings’ table because there was no useful information to
include.
Primary outcomes
1. Participant-reported pain relief of 30% or greater.
2. Participant-reported pain relief of 50% or greater.
3. PGIC much or very much improved.
4. PGIC very much improved.
Secondary outcomes
1. Any pain-related outcome indicating some improvement.
2. Withdrawals due to lack of efficacy, adverse events, and for
any cause.
3. Participants experiencing any adverse event.
4. Participants experiencing any serious adverse event. Serious
adverse events typically include any untoward medical
occurrence or effect that at any dose results in death, is life-
threatening, requires hospitalisation or prolongation of existing
hospitalisation, results in persistent or significant disability or
incapacity, is a congenital anomaly or birth defect, is an
’important medical event’ that may jeopardise the person, or may
require an intervention to prevent one of the above
characteristics or consequences.
5. Specific adverse events, particularly somnolence and
dizziness.
Search methods for identification of studies
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Electronic searches
We search the following databases, without language restrictions.
1. Cochrane Central Register of Controlled Trials
(CENTRAL, via the Cochrane Register of Studies Online
database (CRSO)) to 11 June 2015.
2. MEDLINE (via Ovid) from 1946 to 11 June 2015.
3. EMBASE (via Ovid) from 1974 to 11 June 2015.
The search strategies for CENTRAL, MEDLINE, and EMBASE
are listed inAppendix 2, Appendix 3, andAppendix 4, respectively.
Searching other resources
We reviewed the bibliographies of any RCTs identified and re-
view articles, and searched clinical trial databases (ClinicalTri-
als.gov (ClinicalTrials.gov) andWorld Health Organization Inter-
national Clinical Trials Registry Platform (ICTRP) (apps.who.int/
trialsearch/)) to identify additional published or unpublished data.
We did not contact investigators or study sponsors.
Data collection and analysis
We planned to perform separate analyses according to particular
neuropathic pain conditions. We planned to combine different
neuropathic pain conditions in analyses for exploratory purposes
only.
Selection of studies
We determined eligibility by reading the abstract of each study
identified by the search.We eliminated studies that clearly did not
satisfy the inclusion criteria, and obtained full copies of the re-
maining studies. Two review authors made the decisions. Two re-
view authors read these studies independently and reached agree-
ment by discussion. We did not anonymise the studies in any way
before assessment. We have included a Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) flow chart
(Liberati 2009; Figure 1).
Figure 1. Study flow diagram.
Data extraction and management
We planned that two review authors would extract data indepen-
dently using a standard form and check for agreement before entry
intoReviewManager 5 (RevMan 2014), or any other analysis tool.
We planned to include information about the pain condition and
number of participants treated, drug and dosing regimen, study
design (placebo or active control), study duration and follow-up,
analgesic outcome measures and results, withdrawals, and adverse
events (participants experiencing any adverse event or serious ad-
verse event).
Assessment of risk of bias in included studies
We planned to use the Oxford Quality Score as the basis for in-
clusion (Jadad 1996), limiting inclusion to studies that are ran-
domised and double-blind as a minimum.
Two review authors would have independently assessed risk of
bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
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and adapted from those used by the Cochrane Pregnancy and
Childbirth Group, with any disagreements resolved by discussion.
We planned to assess the following for each study.
1. Random sequence generation (checking for possible
selection bias). We planned to assess the method used to generate
the allocation sequence as: low risk of bias (any truly random
process, random number table, computer random number
generator); unclear risk of bias (when the method used to
generate the sequence is not clearly stated). We intended to
exclude studies at a high risk of bias that used a non-random
process (odd or even date of birth, hospital or clinic record
number).
2. Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during, recruitment,
or changed after assignment. We planned to assess the methods
as: low risk of bias (telephone or central randomisation,
consecutively numbered, sealed, opaque envelopes); unclear risk
of bias (when method not clearly stated). We intended to exclude
studies that did not conceal allocation and were, therefore, at a
high risk of bias (open list).
3. Blinding of outcome assessment (checking for possible
detection bias). We planned to assess the methods used to blind
study participants and outcome assessors from knowledge of
which intervention a participant received. We planned to assess
the methods as: low risk of bias (study stated that it was blinded
and described the method used to achieve blinding, identical
tablets, matched in appearance and smell); unclear risk of bias
(study stated that it was blinded but did not provide an adequate
description of how it was achieved). We intended to exclude
studies at a high risk of bias that were not double-blind.
4. Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data). We planned to assess the methods used to deal
with incomplete data as: low risk of bias (less than 10% of
participants did not complete the study or used ’baseline
observation carried forward’ analysis, or both); unclear risk of
bias (used LOCF analysis); or high risk of bias (used ’completer’
analysis).
5. Size of study (checking for possible biases confounded by
small size). We planned to assess studies as being at low risk of
bias (200 participants or more per treatment arm); unclear risk
of bias (50 to 199 participants per treatment arm); or high risk of
bias (fewer than 50 participants per treatment arm).
Measures of treatment effect
We planned to calculate NNTs as the reciprocal of the absolute
risk reduction (ARR; McQuay 1998). For unwanted effects, the
NNTbecomes the number needed to treat for an additional harm-
ful outcome (NNH) and is calculated in the same manner. We
planned to use dichotomous data to calculate risk ratio (RR) with
95% confidence intervals (CI) using a fixed-effect model unless
we found significant statistical heterogeneity (see Assessment of
heterogeneity). We planned not to use continuous data in analy-
ses, and intended to extract and use continuous data, which prob-
ably reflects efficacy and utility poorly, only if useful for illustrative
purposes only.
Unit of analysis issues
We accepted randomisation to individual participant only. We
planned to split the control treatment arm between active treat-
ment arms in a single study if the active treatment arms were not
combined for analysis.
Dealing with missing data
Weplanned to use intention-to-treat (ITT) analysis where the ITT
population consisted of participants who were randomised, took
at least one dose of the assigned study medication, and provided
at least one post-baseline assessment. We planned to assign zero
improvement to missing participants wherever possible.
Assessment of heterogeneity
Weplanned to deal with clinical heterogeneity by combining stud-
ies that examined similar conditions. We planned to assess statisti-
cal heterogeneity visually (L’Abbé 1987), and using the I2 statistic.
When the I2 value was greater than 50%, we intended to consider
possible reasons for this.
Assessment of reporting biases
The aim of this reviewwas to use dichotomous outcomes of known
utility and of value to people with pain (Hoffman 2010; Moore
2010c; Moore 2010d; Moore 2010e; Moore 2013b). The review
would not depend onwhat the authors of the original studies chose
to report or not, though clearly difficulties might arise in studies
that did not report any dichotomous results.
We planned to assess publication bias using a method designed to
detect the amount of unpublished data with a null effect required
to make any result clinically irrelevant (usually taken to mean an
NNT of 10 or higher; Moore 2008).
Data synthesis
We planned to use a fixed-effect model for meta-analysis. We
would have used a random-effects model for meta-analysis if there
was significant clinical heterogeneity and it was considered appro-
priate to combine studies.
We planned to analyse data for each neuropathic pain condition
in three tiers, according to outcome and freedom from known
sources of bias.
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1. The first tier would use data meeting current best standards,
where studies report the outcome of at least 50% pain intensity
reduction over baseline (or its equivalent), without the use of
LOCF or other imputation method for drop-outs, report an ITT
analysis, last eight or more weeks, have a parallel-group design,
and have at least 200 participants (preferably at least 400) in the
comparison (Moore 1998; Moore 2010a; Moore 2012a; Moore
2012b). We would report these first-tier results first.
2. The second tier would use data from at least 200
participants but where one or more of the first-tier conditions
above was not met (reporting at least 30% pain intensity
reduction, using LOCF or a completer analysis, or lasting four to
eight weeks).
3. The third tier of evidence would relate to data from fewer
than 200 participants, or where there were expected to be
significant problems because, for example, of very short duration
studies of less than four weeks; where there was major
heterogeneity between studies; or where there were shortcomings
in allocation concealment, attrition, or incomplete outcome
data. For this third tier of evidence, no data synthesis is
reasonable and may be misleading, but an indication of
beneficial effects might be possible.
Subgroup analysis and investigation of heterogeneity
We planned to carry out analyses according to individual neuro-
pathic pain conditions because placebo response rates for the same
outcome can vary between conditions, as can the drug-specific ef-
fects (Moore 2009).
We did not plan subgroup analyses since experience of previous
reviews indicated that there would be too few data for any mean-
ingful subgroup analysis (Gaskell 2014; McNicol 2013).
Sensitivity analysis
We planned no sensitivity analysis because the evidence base was
known to be too small to allow reliable analysis; we would not
pool results from neuropathic pain of different origins in the pri-
mary analyses. We planned to examine details of dose-escalation
schedules in the unlikely situation that this could provide some
basis for a sensitivity analysis.
R E S U L T S
Description of studies
Results of the search
Electronic searches identified 10 possible studies for inclusion,
and searches of ClinicalTrials.gov identified one study. Figure 1
shows the flow diagram of study selection. No study matched the
inclusion criteria.Wedidnot identify any studies testing the effects
of buprenorphine in neuropathic pain that satisfied our inclusion
criteria.
Included studies
There were no included studies.
Excluded studies
We excluded 11 studies. Two were reviews with no primary clini-
cal trial data (Kress 2009; Sittl 2005). Five were randomised trials,
but included a mix of pain conditions, including musculoskeletal
pain and cancer pain, and did not report results for the (often few)
participants with neuropathic pain (Böhme 2003; Landau 2007;
NCT00312195; Sittl 2003; Sorge 2004). Two were not dou-
ble-blind (Canneti 2013; Penza 2008), one was not randomised
(Rodriguez-Lopez 2004), and one was a short duration study ex-
amining opioid conversion ratios in a small number of participants
after surgery (Benedetti 1998).
Risk of bias in included studies
There were no studies to evaluate.
Effects of interventions
There were no studies to evaluate.
D I S C U S S I O N
Summary of main results
We found no studies assessing the efficacy of buprenorphine in
neuropathic pain to include in this review. Several studies, some
randomised, had assessed buprenorphine, usually as a transdermal
patch, in chronic pain. This was usually a mix of various types
of pain, typically but not always with musculoskeletal pain pre-
dominating. None reported results by type of pain condition, and
none of the studies provided a thorough assessment that any of
the participants had pain with a neuropathic component. Using
data from those studies would be little more than a guess.
As best we know, there is no evidence to support or refute the use
of buprenorphine for treating neuropathic pain. This is despite
the fact that one UK survey found that weak and strong opioids
were used frequently for treating neuropathic pain, either alone
or in combination with other drugs (Hall 2013). The lack of evi-
dence for long-term benefit with buprenorphine reflects a similar
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result with oxycodone and other opioids (Gaskell 2014; McNicol
2013). The lack of evidence of efficacy combined with substantial
evidence of harm has led to calls for referral to a pain management
specialist (ideally with expertise in opioid use) if daily dosing ex-
ceeds 8 to 100 mg morphine equivalents a day, particularly if pain
and function are not substantially improved (Franklin 2014).
Overall completeness and applicability of
evidence
There was no evidence for inclusion.
Quality of the evidence
There was no evidence for inclusion.
Potential biases in the review process
We know of no potential biases in the review process. It is unlikely
that there is a large body of unpublished evidence showing a large
effect from buprenorphine in neuropathic pain.
Agreements and disagreements with other
studies or reviews
This review agrees with previous reviews and Cochrane reviews
that there appear to be no clinical studies specifically assessing the
efficacy of buprenorphine, at any dose or formulation, in neuro-
pathic pain (Kress 2009; McNicol 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with neuropathic pain
There is insufficient evidence to support or refute the suggestion
that buprenorphine has any efficacy in any neuropathic pain con-
dition.
For clinicians
There is insufficient evidence to support or refute the suggestion
that buprenorphine has any efficacy in any neuropathic pain con-
dition.
For policy makers
There is insufficient evidence to support or refute the suggestion
that buprenorphine has any efficacy in any neuropathic pain con-
dition. In the absence of any supporting evidence, it should prob-
ably not be recommended, except at the discretion of a pain spe-
cialist with particular expertise in opioid use.
For funders
There is insufficient evidence to support or refute the suggestion
that buprenorphine has any efficacy in any neuropathic pain con-
dition. In the absence of any supporting evidence, it should prob-
ably not be recommended, except at the discretion of a pain spe-
cialist with particular expertise in opioid use.
Implications for research
Large, robust randomised trials with patient-centred outcomes
would be required to produce evidence to support or refute efficacy
of buprenorphine in neuropathic pain. The necessary design of
such trials is well established, but for opioids in neuropathic pain,
the outcomes should be those of at least 30% and at least 50% pain
intensity reduction over baseline at the end of a trial of 12 weeks’
duration in participants continuing on treatment. Withdrawal for
any reason should be regarded as treatment failure, and LOCF
analysis should not be used. The reason for this is that, in chronic
pain, opioids frequently produce withdrawal rates of 50%ormore,
meaning that LOCF analysis can overstate treatment efficacy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Benedetti 1998 Not randomised comparison of buprenorphine versus placebo; intravenous buprenorphine; short term
Böhme 2003 Various chronic pain diagnoses, plus cancer
Canneti 2013 Not double-blind
Kress 2009 Review
Landau 2007 75% of participants had pain of back, knee, or hip. Not neuropathic pain
NCT00312195 Non-cancer pain, without separate description of neuropathic pain
Penza 2008 Not double-blind
Rodriguez-Lopez 2004 Not a randomised controlled trial
Sittl 2003 Fewer than 20% participants had neuropathic pain, not separately described
Sittl 2005 Review
Sorge 2004 Various chronic pain diagnoses, plus cancer
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D A T A A N D A N A L Y S E S
This review has no analyses.
WH A T ’ S N E W
Date Event Description
11 October 2017 Review declared as stable No new studies likely to change the conclusions are expected
H I S T O R Y
Date Event Description
7 June 2017 Review declared as stable See Published notes.
C O N T R I B U T I O N S O F A U T H O R S
SD and RAM wrote the protocol.
SD, PW, and RAM searched for and selected studies for inclusion, and carried out data extraction.
All review authors were involved in writing the full review.
RAM will be responsible for any updates required.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol included both CRPS I and CRPS II as a diagnosis of neuropathic pain. We have now removed CRPS I because it is no
longer considered to be neuropathic pain. There were no studies in CRPS I.
N O T E S
A restricted search in June 2017 did not identify any potentially relevant studies likely to change the conclusions. We are not aware of
any ongoing studies in this area. Therefore, this review has now been stabilised following discussion with the authors and editors. If
appropriate, we will update the review if new evidence likely to change the conclusions is published, or if standards change substantially
which necessitate major revisions.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Analgesics, Opioid [∗therapeutic use]; Buprenorphine [∗therapeutic use]; Neuralgia [∗drug therapy]
MeSH check words
Adult; Humans
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